Stakeholder Preference Studies
Evaluate the preferences of patients, HCPs, caregivers and payers to demonstrate product value.

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasing their focus on patient preference in regulatory submission packages. Kantar will recommend the optimal stated preference methodology, e.g. discrete choice experiment (DCE), best-worst scaling (BWS), etc., to meet your research objectives throughout the product lifecycle. We will also apply our global recruiting capabilities to ensure recruitment with the right degree of precision.
Client results
Also within Health
-
Clinical Research & Medical Affairs
-
Commercial Planning
-
Real-World Evidence
-
Specialist Consulting
-
Data and Analytics